Page 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON , DC 20549 Form 10 - K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31 , 2020 of CUMBERLAND PHARMACEUTICALS INC . A Tennessee Corporation IRS Employer Identification No. 62-1765329 Commission file number 001-33637 Title of each class Common Stock , $ 0.00 par value 2525 West End Avenue , Suite 950 Nashville , Tennessee 37203 ( 615 ) 255-0068 Securities registered pursuant to Section 12 ( b ) of the Act : Trading Symbol ( s ) Name of each exchange on which registered Nasdaq Global Select Market CPIX per share Securities registered pursuant to Section 12 ( g ) of the Act : None Cumberland Pharmaceuticals Inc. is not a well - known seasoned issuer , as defined in Rule 405 of the Securities Act . Cumberland Pharmaceuticals Inc. is required to file reports pursuant to Section 13 or Section 15 ( d ) of the Act . Cumberland Pharmaceuticals Inc. ( 1 ) has filed all reports required to be filed by Section 13 or 15 ( d ) of the Securities Exchange Act of 1934 during the preceding 12 months , and ( 2 ) has been subject to such filing requirements for the past 90 days . Cumberland Pharmaceuticals Inc. has submitted electronically and posted on its corporate Web site every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S - T ( §232.405 of this chapter ) during the preceding 12 months . Cumberland Pharmaceuticals Inc. is a non - accelerated filer and a smaller reporting company as defined in Rule 12b - 2 of the Exchange Act and is not a shell company . Cumberland Pharmaceuticals Inc. has not filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404 ( b ) of the Sarbanes - Oxley Act by the registered public accounting firm that prepared and issued its audit report . The aggregate market value of common stock held by non - affiliates as of June 30 , 2020 was $ 30,639,333 . The number of shares of the registrant's Common Stock , no par value , outstanding as of March 8 , 2021 was 14,920,655 . DOCUMENTS INCORPORATED BY REFERENCE Certain information required in Part III of Form 10 - K is incorporated by reference from the registrant's Proxy Statement for its 2021 annual meeting of shareholders .